Azenta, Inc.
AZTAHealthcareNASDAQMedical Instruments & Supplies · Last scanned Jul 18, 2026
Scan Results
Daily timeframeAzenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific,. Valued at $1.21B, AZTA is a small-cap name in its sector. It operates through Sample Management Solutions and Multiomics segments.
Market Cap
$1.21B
Beta
1.37
P/E (TTM)
—
P/E (Fwd)
42.82
EPS (TTM)
$-2.41
EPS (Fwd)
$0.61
ROE
-6.8%
ROA
-0.6%
Cash
$380.5M
Total Debt
$55.7M
Free CF
$101.3M
52W Change
-15.6%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $380.5M in cash comfortably exceeding the $55.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $101.3M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -6.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $555.5M (2022) to $593.8M (2025).
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Azenta, Inc. and its sector.